Outcomes in COVID-19 adalimumab studies

0 0.5 1 1.5+ All studies 0% 1 68 Improvement, Studies, Patients Relative Risk Mortality 0% 1 68 Ventilation -33% 1 68 ICU admission 0% 1 68 RCTs 0% 1 68 Late 0% 1 68 Adalimumab for COVID-19 c19early.org December 2025 Favorsadalimumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] death 4/34 4/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.27-3.68] 4/34 4/34 no change All studies 0% 1.00 [0.27-3.68] 4/34 4/34 no change 1 adalimumab COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] 4/34 4/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.27-3.68] 4/34 4/34 no change All studies 0% 1.00 [0.27-3.68] 4/34 4/34 no change 1 adalimumab COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) -33% 1.33 [0.32-5.51] 4/34 3/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Late treatment -33% 1.33 [0.32-5.51] 4/34 3/34 33% higher risk All studies -33% 1.33 [0.32-5.51] 4/34 3/34 33% higher risk 1 adalimumab COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.32-3.14] 5/34 5/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.32-3.14] 5/34 5/34 no change All studies 0% 1.00 [0.32-3.14] 5/34 5/34 no change 1 adalimumab COVID-19 ICU result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] death 4/34 4/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.27-3.68] 4/34 4/34 no change All studies 0% 1.00 [0.27-3.68] 4/34 4/34 no change 1 adalimumab COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] death 4/34 4/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.27-3.68] 4/34 4/34 no change All studies 0% 1.00 [0.27-3.68] 4/34 4/34 no change 1 adalimumab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] 4/34 4/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.27-3.68] 4/34 4/34 no change All studies 0% 1.00 [0.27-3.68] 4/34 4/34 no change 1 adalimumab COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] death 4/34 4/34 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.27-3.68] 4/34 4/34 no change All studies 0% 1.00 [0.27-3.68] 4/34 4/34 no change 1 adalimumab COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors adalimumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fakharian (RCT) 0% 1.00 [0.27-3.68] death 4/34 4/34 Improvement, RR [CI] Treatment Control Fakharian (RCT) -33% 1.33 [0.32-5.51] ventilation 4/34 3/34 Fakharian (RCT) 0% 1.00 [0.32-3.14] ICU 5/34 5/34 Adalimumab COVID-19 outcomes c19early.org December 2025 Favors adalimumab Favors control